PMID- 37842456
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 9
DP  - 2023 Sep
TI  - Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for 
      Secondary Central Nervous System Lymphoma: A Case Series.
PG  - e45088
LID - 10.7759/cureus.45088 [doi]
LID - e45088
AB  - Relapsed or refractory (R/R) large B cell lymphoma (LBCL) presenting as secondary 
      central nervous system lymphoma (SCNSL) carries a poor prognosis, with a median 
      survival time of two to five months. Chimeric antigen receptor (CAR)-T cell 
      therapy has been approved in R/R LBCL, but studies are ongoing to understand its 
      efficacy and safety for SCNSL. Axicabtagene ciloleucel or tisagenlecleucel have 
      been shown to attain high response rates in some retrospective studies; however, 
      response durability continues to be unclear. Our study is a case series of three 
      patients with R/R SCNSL who were treated with tisagenlecleucel. One patient 
      achieved a complete response 30 days after CAR-T therapy but developed disease 
      progression on day +100 imaging. The second patient had a partial response and 
      eventual disease progression with ultimately death. The third patient died from 
      central nervous system complications of CAR-T therapy. Two of the three patients 
      developed immune effector cell-associated neurotoxicity syndrome grade 4 and 
      cytokine release syndrome grade 1 toxicities. Our series of three patients 
      demonstrates that R/R SCNSL can elicit a response with CAR-T therapy, although 
      with a limited duration response.
CI  - Copyright (c) 2023, Dhaliwal et al.
FAU - Dhaliwal, Armaan
AU  - Dhaliwal A
AD  - Internal Medicine, University of Arizona College of Medicine, Tucson, USA.
FAU - Mann, Shivtaj
AU  - Mann S
AD  - Hematology and Medical Oncology, University of Arizona Cancer Center, Tucson, 
      USA.
LA  - eng
PT  - Case Reports
DEP - 20230912
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10568653
OTO - NOTNLM
OT  - chimeric antigen receptor t cell therapy
OT  - double hit lymphoma
OT  - relapsed/refractory
OT  - secondary cns lymphoma
OT  - tisagenlecleucel
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/10/16 06:48
MHDA- 2023/10/16 06:49
PMCR- 2023/09/12
CRDT- 2023/10/16 04:53
PHST- 2023/09/12 00:00 [accepted]
PHST- 2023/10/16 06:49 [medline]
PHST- 2023/10/16 06:48 [pubmed]
PHST- 2023/10/16 04:53 [entrez]
PHST- 2023/09/12 00:00 [pmc-release]
AID - 10.7759/cureus.45088 [doi]
PST - epublish
SO  - Cureus. 2023 Sep 12;15(9):e45088. doi: 10.7759/cureus.45088. eCollection 2023 
      Sep.